Zoetis Inc. - Understand $zts stock

$ZTS Market Cap: $79.1 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$9.152B

TTM

Gross Margin

70.05%

TTM

Net Earnings

$2.430B

TTM

Current Assets

$6.282B

Q3 2024

Current Liabilities

$1.702B

Q3 2024

Current Ratio

369.1%

Q3 2024

Total Assets

$14.36B

Q3 2024

Total Liabilities

$9.123B

Q3 2024

Book Value

$5.234B

Q3 2024

Cash

$1.714B

Q3 2024

P/E

32.55

Nov 29, 2024 EST

Free Cash Flow

$2.308B

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue	$8.544B	$8.080B	$7.776B	$6.675B	$6.260B	$5.825B	$5.307B	$4.888B	$4.765B	$4.785B	$4.561B	$4.336B	$4.233B	$3.582B	$2.760B
YoY Change	5.74%	3.91%	16.49%	6.63%	7.47%	9.76%	8.57%	2.58%	-0.42%	4.91%	5.19%	2.43%	18.17%	29.78%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue	$8.544B	$8.080B	$7.776B	$6.675B	$6.260B	$5.825B	$5.307B	$4.888B	$4.765B	$4.785B	$4.561B	$4.336B	$4.233B	$3.582B	$2.760B
Cost Of Revenue	$2.561B	$2.454B	$2.303B	$2.057B	$1.992B	$1.911B	$1.775B	$1.666B	$1.738B	$1.717B	$1.669B	$1.563B	$1.652B	$1.444B	$1.025B
Gross Profit	$5.983B	$5.626B	$5.473B	$4.618B	$4.268B	$3.914B	$3.532B	$3.222B	$3.027B	$3.068B	$2.892B	$2.773B	$2.581B	$2.138B	$1.735B
Gross Profit Margin	70.03%	69.63%	70.38%	69.18%	68.18%	67.19%	66.55%	65.92%	63.53%	64.12%	63.41%	63.95%	60.97%	59.69%	62.86%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Selling, General & Admin	$2.151B	$2.009B	$2.001B	$1.726B	$1.638B	$1.484B	$1.334B	$1.364B	$1.532B	$1.643B	$1.613B	$1.470B	$1.453B	$1.365B	$1.055B
YoY Change	7.07%	0.4%	15.93%	5.37%	10.38%	11.24%	-2.2%	-10.97%	-6.76%	1.86%	9.73%	1.17%	6.45%	29.38%
% of Gross Profit	35.95%	35.71%	36.56%	37.38%	38.38%	37.92%	37.77%	42.33%	50.61%	53.55%	55.77%	53.01%	56.3%	63.84%	60.81%
Research & Development	$614.0M	$539.0M	$508.0M	$463.0M	$457.0M	$432.0M	$382.0M	$376.0M	$364.0M	$396.0M	$399.0M	$409.0M	$427.0M	$411.0M	$366.0M
YoY Change	13.91%	6.1%	9.72%	1.31%	5.79%	13.09%	1.6%	3.3%	-8.08%	-0.75%	-2.44%	-4.22%	3.89%	12.3%
% of Gross Profit	10.26%	9.58%	9.28%	10.03%	10.71%	11.04%	10.82%	11.67%	12.03%	12.91%	13.8%	14.75%	16.54%	19.22%	21.1%
Depreciation & Amortization	$491.0M	$465.0M	$448.0M	$441.0M	$412.0M	$308.0M	$242.0M	$240.0M	$199.0M	$204.0M	$209.0M	$200.0M	$205.0M	$185.0M	$124.0M
YoY Change	5.59%	3.79%	1.59%	7.04%	33.77%	27.27%	0.83%	20.6%	-2.45%	-2.39%	4.5%	-2.44%	10.81%	49.19%
% of Gross Profit	8.21%	8.27%	8.19%	9.55%	9.65%	7.87%	6.85%	7.45%	6.57%	6.65%	7.23%	7.21%	7.94%	8.65%	7.15%
Operating Expenses	$2.765B	$2.548B	$2.509B	$2.189B	$2.095B	$1.916B	$1.716B	$1.740B	$1.896B	$2.039B	$2.012B	$1.879B	$1.880B	$1.808B	$1.448B
YoY Change	8.52%	1.55%	14.62%	4.49%	9.34%	11.66%	-1.38%	-8.23%	-7.01%	1.34%	7.08%	-0.05%	3.98%	24.86%
Operating Profit	$3.218B	$3.078B	$2.964B	$2.429B	$2.173B	$1.998B	$1.816B	$1.482B	$1.131B	$1.029B	$880.0M	$894.0M	$701.0M	$330.0M	$287.0M
YoY Change	4.55%	3.85%	22.03%	11.78%	8.76%	10.02%	22.54%	31.03%	9.91%	16.93%	-1.57%	27.53%	112.42%	14.98%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Interest Expense	$239.0M	$221.0M	$224.0M	$231.0M	$223.0M	$206.0M	$175.0M	$166.0M	$124.0M	$117.0M	$113.0M	$31.00M	$36.00M	-$37.00M	-$26.00M
YoY Change	8.14%	-1.34%	-3.03%	3.59%	8.25%	17.71%	5.42%	33.87%	5.98%	3.54%	264.52%	-13.89%	-197.3%	42.31%
% of Operating Profit	7.43%	7.18%	7.56%	9.51%	10.26%	10.31%	9.64%	11.2%	10.96%	11.37%	12.84%	3.47%	5.14%	-11.21%	-9.06%
Other Income/Expense, Net	$159.0M	-$40.00M	-$48.00M	-$17.00M	$57.00M	$83.00M	-$6.000M	$2.000M	-$81.00M	-$7.000M	$9.000M	$46.00M	-$48.00M
YoY Change	-497.5%	-16.67%	182.35%	-129.82%	-31.33%	-1483.33%	-400.0%	-102.47%	1057.14%	-177.78%	-80.43%	-195.83%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Pretax Income	$2.936B	$2.656B	$2.488B	$1.996B	$1.801B	$1.690B	$1.525B	$1.228B	$545.0M	$820.0M	$690.0M	$710.0M	$394.0M	$178.0M	-$148.0M
YoY Change	10.54%	6.75%	24.65%	10.83%	6.57%	10.82%	24.19%	125.32%	-33.54%	18.84%	-2.82%	80.2%	121.35%	-220.27%
Income Tax	$596.0M	$545.0M	$454.0M	$360.0M	$301.0M	$266.0M	$663.0M	$409.0M	$206.0M	$233.0M	$187.0M	$274.0M	$146.0M	$67.00M	-$47.00M
% Of Pretax Income	20.3%	20.52%	18.25%	18.04%	16.71%	15.74%	43.48%	33.31%	37.8%	28.41%	27.1%	38.59%	37.06%	37.64%
Net Earnings	$2.344B	$2.114B	$2.037B	$1.638B	$1.500B	$1.428B	$864.0M	$821.0M	$339.0M	$583.0M	$504.0M	$436.0M	$245.0M	$110.0M	-$100.0M
YoY Change	10.88%	3.78%	24.36%	9.2%	5.04%	65.28%	5.24%	142.18%	-41.85%	15.67%	15.6%	77.96%	122.73%	-210.0%
Net Earnings / Revenue	27.43%	26.16%	26.2%	24.54%	23.96%	24.52%	16.28%	16.8%	7.11%	12.18%	11.05%	10.06%	5.79%	3.07%	-3.62%
Basic Earnings Per Share	$5.08	$4.51	$4.29	$3.44	$3.14	$2.96	$1.76	$1.66	$0.68	$1.16	$1.01	$0.87	$0.49
Diluted Earnings Per Share	$5.07	$4.49	$4.27	$3.42	$3.11	$2.93	$1.75	$1.65	$0.68	$1.16	$1.01	$0.87	$0.49	$220.0K	-$200.0K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Cash & Short-Term Investments	$2.039B	$3.577B	$3.482B	$3.602B	$1.932B	$1.701B	$1.564B	$727.0M	$1.154B	$882.0M	$610.0M	$317.0M	$79.00M	$63.00M
YoY Change	-43.0%	2.73%	-3.33%	86.44%	13.58%	8.76%	115.13%	-37.0%	30.84%	44.59%	92.43%	301.27%	25.4%
Cash & Equivalents	$2.039B	$3.577B	$3.482B	$3.602B	$1.932B	$1.602B	$1.564B	$727.0M	$1.154B	$882.0M	$610.0M	$317.0M	$79.00M	$63.00M
Short-Term Investments					$0.00	$99.00M
Other Short-Term Assets	$436.0M	$369.0M	$392.0M	$368.0M	$320.0M	$271.0M	$228.0M	$248.0M	$272.0M	$314.0M	$316.0M	$302.0M	$298.0M	$285.0M
YoY Change	18.16%	-5.87%	6.52%	15.0%	18.08%	18.86%	-8.06%	-8.82%	-13.38%	-0.63%	4.64%	1.34%	4.56%
Inventory	$2.564B	$2.345B	$1.923B	$1.628B	$1.410B	$1.391B	$1.427B	$1.502B	$1.467B	$1.289B	$1.293B	$1.345B	$1.063B	$995.0M
Prepaid Expenses
Receivables	$1.304B	$1.215B	$1.133B	$1.013B	$1.086B	$1.036B	$998.0M	$913.0M	$937.0M	$980.0M	$1.138B	$900.0M	$871.0M	$773.0M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.343B	$7.506B	$6.930B	$6.611B	$4.748B	$4.399B	$4.217B	$3.390B	$3.830B	$3.465B	$3.357B	$2.864B	$2.311B	$2.116B
YoY Change	-15.49%	8.31%	4.83%	39.24%	7.93%	4.32%	24.4%	-11.49%	10.53%	3.22%	17.21%	23.93%	9.22%
Property, Plant & Equipment	$3.443B	$2.973B	$2.603B	$2.394B	$2.129B	$1.658B	$1.435B	$1.381B	$1.307B	$1.318B	$1.295B	$1.241B	$1.243B	$1.148B
YoY Change	15.81%	14.21%	8.73%	12.45%	28.41%	15.54%	3.91%	5.66%	-0.83%	1.78%	4.35%	-0.16%	8.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$403.0M	$320.0M	$211.0M	$200.0M	$186.0M	$155.0M	$155.0M	$169.0M	$131.0M	$102.0M	$121.0M	$304.0M	$240.0M	$162.0M
YoY Change	25.94%	51.66%	5.5%	7.53%	20.0%	0.0%	-8.28%	29.01%	28.43%	-15.7%	-60.2%	26.67%	48.15%
Total Long-Term Assets	$7.943B	$7.419B	$6.970B	$6.998B	$6.797B	$6.378B	$4.369B	$4.259B	$4.083B	$3.123B	$3.201B	$3.398B	$3.400B	$3.168B
YoY Change	7.06%	6.44%	-0.4%	2.96%	6.57%	45.98%	2.58%	4.31%	30.74%	-2.44%	-5.8%	-0.06%	7.32%
Total Assets	$14.29B	$14.93B	$13.90B	$13.61B	$11.55B	$10.78B	$8.586B	$7.649B	$7.913B	$6.588B	$6.558B	$6.262B	$5.711B	$5.284B
YoY Change
Accounts Payable	$411.0M	$405.0M	$436.0M	$457.0M	$301.0M	$313.0M	$261.0M	$265.0M	$293.0M	$290.0M	$506.0M	$319.0M	$214.0M	$206.0M
YoY Change	1.48%	-7.11%	-4.6%	51.83%	-3.83%	19.92%	-1.51%	-9.56%	1.03%	-42.69%	58.62%	49.07%	3.88%
Accrued Expenses	$1.113B	$1.025B	$1.143B	$891.0M	$854.0M	$753.0M	$668.0M	$688.0M	$910.0M	$713.0M	$799.0M	$320.0M	$273.0M	$222.0M
YoY Change	8.59%	-10.32%	28.28%	4.33%	13.41%	12.72%	-2.91%	-24.4%	27.63%	-10.76%	149.69%	17.22%	22.97%
Deferred Revenue
YoY Change
Short-Term Debt	$3.000M	$2.000M	$0.00	$4.000M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	50.0%		-100.0%
Long-Term Debt Due	$1.000M	$1.350B	$0.00	$600.0M	$500.0M	$9.000M		$0.00	$405.0M	$7.000M	$15.00M	$73.00M	$0.00	$38.00M
YoY Change	-99.93%		-100.0%	20.0%	5455.56%			-100.0%	5685.71%	-53.33%	-79.45%		-100.0%
Total Short-Term Liabilities	$1.889B	$3.167B	$1.797B	$2.170B	$1.806B	$1.223B	$1.094B	$1.117B	$1.781B	$1.086B	$1.415B	$1.123B	$843.0M	$808.0M
YoY Change	-40.35%	76.24%	-17.19%	20.16%	47.67%	11.79%	-2.06%	-37.28%	64.0%	-23.25%	26.0%	33.21%	4.33%
Long-Term Debt	$6.572B	$6.552B	$6.592B	$6.595B	$5.947B	$6.443B	$4.953B	$4.468B	$4.463B	$3.624B	$3.642B	$509.0M	$575.0M	$673.0M
YoY Change	0.31%	-0.61%	-0.05%	10.9%	-7.7%	30.08%	10.85%	0.11%	23.15%	-0.49%	615.52%	-11.48%	-14.56%
Other Long-Term Liabilities	$688.0M	$661.0M	$647.0M	$693.0M	$650.0M	$452.0M	$373.0M	$321.0M	$314.0M	$264.0M	$217.0M	$266.0M	$246.0M	$241.0M
YoY Change	4.08%	2.16%	-6.64%	6.62%	43.81%	21.18%	16.2%	2.23%	18.94%	21.66%	-18.42%	8.13%	2.07%
Total Long-Term Liabilities	$7.260B	$7.213B	$7.239B	$7.288B	$6.597B	$6.895B	$5.326B	$4.789B	$4.777B	$3.888B	$3.859B	$775.0M	$821.0M	$914.0M
YoY Change	0.65%	-0.36%	-0.67%	10.47%	-4.32%	29.46%	11.21%	0.25%	22.87%	0.75%	397.94%	-5.6%	-10.18%
Total Liabilities	$9.289B	$10.52B	$9.357B	$9.840B	$8.837B	$8.592B	$6.816B	$6.162B	$6.845B	$5.277B	$5.618B	$2.236B	$1.991B	$1.940B
YoY Change	-11.7%	12.43%	-4.91%	11.35%	2.85%	26.06%	10.61%	-9.98%	29.71%	-6.07%	151.25%	12.31%	2.63%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Basic Shares Outstanding	461.2M shares	468.9M shares	474.3M shares	475.5M shares	478.1M shares	483.1M shares	489.9M shares	495.7M shares	499.7M shares	501.1M shares	500.0M shares	500.0M shares	500.0M shares
Diluted Shares Outstanding	462.3M shares	470.4M shares	476.7M shares	478.6M shares	481.8M shares	486.9M shares	493.2M shares	498.2M shares	502.0M shares	502.0M shares	500.3M shares	500.0M shares	500.0M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $79.098 Billion

About Zoetis Inc.

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,100 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The company is engaged in commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

Industry: Pharmaceutical Preparations Peers: BRISTOL MYERS SQUIBB CO Catalent, Inc. ELI LILLY & Co JOHNSON & JOHNSON Merck & Co., Inc. Organon & Co. PFIZER INC Royalty Pharma plc Viatris Inc